A Study of RO7617991 in Patients With Locally Advanced or Metastatic MAGE-A4-Positive Solid Tumors

Sponsor
Genentech, Inc.
Study ID
NCT06372574
Phase
PHASE1
Status
Withdrawn

Conditions

  • Recurrent Cancer
  • Refractory Cancer
  • Solid Tumor, Adult

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • RO7617991 — DRUG
    RO7617991 will be administered by intravenous (IV) infusion. Treatment will continue until unacceptable toxicity or loss of clinical benefit as determined by the investigator.
  • Tocilizumab — DRUG
    Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.

Study Details

This study will evaluate the safety, tolerability, and pharmacokinetics of RO7617991, and will make a preliminary assessment of the anti-tumor activity of RO7617991 in human leukocyte antigen (HLA)-A\*02 eligible patients with locally advanced or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive solid tumors.

Key Dates

Start date
Sep 30, 2024
Status verified
Aug 2024
Primary completion
Feb 1, 2028
Completion
Feb 1, 2028

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: RO7617991 Dose Escalation and Expansion

Primary Outcome Measure

Incidence and Severity of Adverse Events [ Time Frame: From first dose until 90 days after the final dose of study treatment (up to approximately 3 years) ]

Related Studies